EUVIMEDEUVIMED entdecken
Crossref

Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043

Michael Powell, Nicholas Battaglia, Lee-Jah Chang, Raffaeloo Cimbro, Stacey Cromer Berman, Tope Oyedele, Angela Pack, Marcelino Padilla, Tiffany Roe, Ann Marie Stanley, Phillip Swanson

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Michael Powell und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction mRNA-encoded virus-like particles (VLPs) are an emerging advancement in vaccine technology, enabling the self-assembly of viral antigens into structures that closely resemble native viruses. This innovative approach to conventional mRNA vaccination may boost vaccine-induced adaptive immune responses and allow for reduced dosing. To evaluate this technology, we developed AZD6563, an mRNA VLP vaccine targeting the COVID-19 XBB1.5 spike variant.

Methods

The phase 1 clinical study ARTEMIS-C was conducted to assess cellular immunogenicity in adults aged 18—64 years and ≥65 years following administration of AZD6563 (5 µg or 10 µg) or the licensed BNT162b2 XBB.1.5 mRNA vaccine (30 µg).

Results

AZD6563 drove spike-specific CD4+ and CD8+ T cell responses comparable to those elicited by higher dose of BNT162b2. Functional analysis of these cells revealed similar cytokine production profiles across groups; however, the 10µg dose of AZD6563 led to higher TCR diversity within the ≥65-year cohort. Notably, expansion of spike-specific B cells was most pronounced in the AZD6563 10µg group, with marked increases in cross-reactive XBB.1.5 spike-specific B cells that also recognized Omicron BA.4/5 and ancestral SARS-CoV-2 variants.

Conclusion

Collectively, these results demonstrate that AZD6563, at reduced doses, matches the cellular immunogenicity of BNT162b2 while enhancing B cell cross-reactivity and TCR diversity in older adults, supporting its potential as a next-generation COVID-19 vaccine candidate. Funding Source n/a Topic Categories Vaccines and Immunotherapy (VAC)

Zitieren

APA

Powell, M., Battaglia, N., Chang, L., Cimbro, R., Berman, S. C., Oyedele, T., Pack, A., Padilla, M., Roe, T., Stanley, A. M., & Swanson, P. (2026). Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.839

Vancouver

Powell M, Battaglia N, Chang L, Cimbro R, Berman SC, Oyedele T, et al. Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.839

BibTeX
@article{Powell2026,
  author = {Powell, Michael and Battaglia, Nicholas and Chang, Lee-Jah and Cimbro, Raffaeloo and Berman, Stacey Cromer and Oyedele, Tope and Pack, Angela and Padilla, Marcelino and Roe, Tiffany and Stanley, Ann Marie and Swanson, Phillip},
  title = {Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.839}
}
Kostenlos starten →